Wainwright Siyaampakula Ramakanth analyst raised the company The target price On Nuvalent (November) To $ 130 from 110 dollars and keeps a purchase classification on shares. The company has reported positive results of the direction line from the study of the 1/2 Arros-1 that evaluates ZideSamtinib to treat non-increasing lung cancer patients from ROS1, informing the investor analyst in a research note, and 62 % of patients. Wamwright believes that the data is “especially encouraging” in 55 patients who received only one line of TKI treatment, which achieved a total response rate of 51 % and 18 months of response 93 %.
The confident investment begins here:
First published on Thefly -The final source of the actual time, the financial financial news in the market. Try now >>
Watch today’s best -performance shares on Tipranks >>
Read more on nuvl:
https://media.zenfs.com/en/tipranks_452/d622151edd421d0d1465b02718e80caa
Source link